Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of JLP-1207 vs Solifenacin/Tamsulosin in Healthy Males
NCT02494349Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of JLP-1207 in benign prostatic hyperplasia (BPH) and overactive bladder (OAB) (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve to the Last Measurable Concentration at 192 hours and Maximum Plasma Concentration at 192 hours. Started Aug 2015; status: completed.
02
Drugs
JLP-1207
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02494349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494349.